Takanashi Ken 的 Form 4 申報
Wave Life Sciences, Inc.（WVE），2026/8/13 申報
- 申報編號
- 0001193125-26-349961
- 申報時間
- 2026/8/13 21:00 ET
- 交易日
- 2026/8/11
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
這份申報列了 1 筆非衍生性交易。公開市場賣出合計 $2.32 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Takanashi KenCIK 0001657768 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/11 | Common Stock | S賣出處分 | −3,864 | $6.01F2 | −$23,222.64 | 20,079 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
備註
On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney